Cancer Stem Cell Antibody-Drug Conjugate Payload

摘要

A challenge with current antibody-drug conjugates (ADCs) is to improve patient outcomes by circumventing drug resistance, disease recurrence, and cancer stem cells. We explore a novel cytotoxic payload, Azonafides, that can be integrated into ADC platforms. This cytotoxin is more stable in circulation, has unique mechanisms of action, and is derived from natural products. Azonafides create an exciting clinical opportunity to improve the therapeutic window, efficacy, and safety of ADCs.